Company Update - Zhou Yan, the Chairman, Executive Director, CEO, and controlling shareholder of AIM Vaccine (06660), has further increased his holdings of the company's H-shares through the open market from January 12, 2024, to April 15, 2024 [1] - Since November 14, 2023, Zhou Yan has cumulatively increased his holdings of the company's H-shares using his own funds, totaling HKD 10,420,212 [1] - Zhou Yan does not rule out the possibility of further increasing his holdings of the company's shares at an appropriate time [1] Operational and Financial Status - The company's operations, financial status, and sales of existing products are all normal as of the announcement date [1] - The development of the company's vaccine pipeline is progressing as planned [1] Shareholding and Regulatory Compliance - Following the recent share increase, the company still meets the sufficient public float requirement under Rule 8.08 of the Listing Rules [1] - The recent share increase did not trigger a mandatory offer obligation under the Takeovers Code [1] - The recent share increase did not result in any change in the company's control [1] Management Confidence - The Board believes that Zhou Yan's continuous share purchases using his own funds reflect his judgment of the company's intrinsic value and future growth potential [1] - Zhou Yan's actions demonstrate his confidence in and recognition of the company's future development, which is conducive to the realization of the company's long-term strategic layout [1]
艾美疫苗(06660)获控股股东周延持续增持股份